Robert Peter Devita

US Patent:

7084156, Aug 1, 2006

Filed:

Nov 22, 2002

Appl. No.:

10/496615

Inventors:

Robert J. DeVita - Westfield NJ, US
Lehua Chang - Ramsey NJ, US
Danny Chaung - Clark NJ, US
MyLe Hoang - Colonia NJ, US
JinLong Jiang - Scotch Plains NJ, US
Peter Lin - Edison NJ, US
Andreas W. Sailer - Edison NJ, US
Jonathan R. Young - Kendall Park NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 215/38
C07D 215/16
A61K 31/47

US Classification:

514312, 514313, 514314, 546159, 546162, 546178

Abstract:

The present invention is concerned with compounds of the general Formula I:.

US Patent:

7468437, Dec 23, 2008

Filed:

Sep 24, 2004

Appl. No.:

10/572444

Inventors:

Robert J. DeVita - Westfield NJ, US
Peter Lin - Edison NJ, US
Sander G. Mills - Scotch Plains NJ, US
Jonathan R. Young - Southborough MA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 239/00
C07D 213/04
C07D 207/00
C07D 233/00
C07D 333/02
C07D 321/00
C07D 307/00
A01N 43/58
A01N 43/64
A61K 31/41
A61K 31/38
A61K 31/335

US Classification:

544358, 544224, 544242, 5483001, 548400, 548215, 5483561, 546249, 546250, 546255, 549 29, 549200, 549429, 514247, 514277, 514359, 514430, 514438, 514449, 5142355, 514249, 51425401, 514326

Abstract:

The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, depression, and anxiety.

US Patent:

7652058, Jan 26, 2010

Filed:

Dec 12, 2005

Appl. No.:

11/792514

Inventors:

Robert J. DeVita - Westfield NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Sander G. Mills - Scotch Plains NJ, US
Jonathan R. Young - Southborough MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/407
C07D 491/052

US Classification:

514414, 548453

Abstract:

The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

US Patent:

7683068, Mar 23, 2010

Filed:

Jun 23, 2006

Appl. No.:

11/920286

Inventors:

Jinlong Jiang - Scotch Plains NJ, US
Robert J. DeVita - Westfield NJ, US
Sanjeev Kumar - Monroe NJ, US
Sander G. Mills - Scotch Plains NJ, US
Richard A. Tschirret-Guth - Lawrenceville NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/497
A61K 31/4035
A61K 31/4439
C07D 209/46
C07D 405/04
C07D 409/04
A61P 29/00

US Classification:

51425505, 514339, 514414, 514416, 544407, 5462771, 548465, 548472

Abstract:

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

US Patent:

7696177, Apr 13, 2010

Filed:

Jun 9, 2006

Appl. No.:

11/922055

Inventors:

Robert J. DeVita - Westfield NJ, US
Greg J. Morriello - Randolph NJ, US
Anthony K. Ogawa - Mountainside NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/67
C07H 7/02
A61K 31/70
A61P 9/10

US Classification:

514 23, 536 53

Abstract:

This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

US Patent:

7704988, Apr 27, 2010

Filed:

Oct 4, 2006

Appl. No.:

11/542966

Inventors:

Robert J. DeVita - Westfield NJ, US
Gregori J. Morriello - Randolph NJ, US
Peter Lin - Edison NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 205/08
A61K 31/397
A61P 9/10
A61P 3/06
C07H 7/02
A61K 31/7052

US Classification:

51421002, 540200, 514 32, 536 174, 564 58, 564 90, 564 98, 549372

Abstract:

This invention provides cholesterol absorption inhibitors of Formula I:.

US Patent:

8124633, Feb 28, 2012

Filed:

Apr 7, 2008

Appl. No.:

12/593168

Inventors:

Robert J. DeVita - Westfield NJ, US
Sander G. Mills - Scotch Plains NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Andrew J. Kassick - Scotch Plains NJ, US
Jianming Bao - Princeton NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/422
C07D 209/02

US Classification:

514376, 514412, 548225, 548452

Abstract:

The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.

US Patent:

20050009815, Jan 13, 2005

Filed:

Nov 22, 2002

Appl. No.:

10/496614

Inventors:

Robert DeVita - Westfield NJ, US
Lehua Chang - Ramsey NJ, US
MyLe Hoang - Colonia NJ, US
JinLong Jiang - Scotch Plains NJ, US
Peter Lin - Edison NJ, US
Andreas Sailer - Edison NJ, US

International Classification:

A61K031/541
A61K031/5377
A61K031/496
A61K031/4709

US Classification:

514227500, 514232500, 514253060, 514313000, 544060000, 544126000, 544363000, 546159000

Abstract:

The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.